Format

Send to

Choose Destination
See comment in PubMed Commons below
Semin Liver Dis. 2004;24 Suppl 1:23-9.

Overview of treatment of hepatitis B: key approaches and clinical challenges.

Author information

1
Section of Gastroenterology and Hepatology, Ochsner Clinic Foundation, New Orleans, Louisiana 70121, USA. rperrillo@ochsner.org

Abstract

The development of nucleoside analogues has been a major advance in the treatment of hepatitis B; however, prolonged monotherapy is associated with drug resistance. Currently, no data in humans indicate that a combination of nucleoside analogues leads to enhanced efficacy. New nucleoside analogues with greater inhibitory effects on hepatitis B virus (HBV) replication being developed could prove to be more effective or less likely to be associated with viral resistance. Interferon still has a role to play in the management of chronic HBV infection. Recent data indicate that the response to interferon may be determined in part by differences in genotype. From a theoretical perspective, a combination of pegylated interferon with one or more nucleosides could induce a higher rate of virological response. Additional studies are needed to further address these issues.

PMID:
15192798
DOI:
10.1055/s-2004-828675
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Georg Thieme Verlag Stuttgart, New York
    Loading ...
    Support Center